News
In Abrupt Reversal, FDA Yanks Ixchiq Vaccine Over Safety Concern
According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events that happened outside the U.S., three of which were in people ages 70 to 82 years and the other in a 55-year-old individual.
The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.
Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...
The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with ...
Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...
Hey, good morning. Today, we see CBER suspend the license for a chikungunya vaccine, look at a push to recall a safety and ...
Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...
A detail of a packaging of the Ixchiq chikungunya vaccine, in a pharmacy in Saint-Denis, La Réunion, is shown March 21. The ...
US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...
Mainland France has seen an explosion of chikungunya outbreaks this summer and local officials are hunting down the tiger mosquitoes responsible for spreading the virus. Meanwhile, the United States ...
There have been 21 cases of chikungunya fever here so far in 2025. Read more at straitstimes.com. Read more at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback